Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
Ori Biotech CEO Jason C. Foster and CTMC Co-Founder + CEO Jason Bock revealed the companies’ findings at the 30th annual International Society for Cell & Gene Therapy (ISCT) Conference in Vancouver, Canada.
- Ori Biotech CEO Jason C. Foster and CTMC Co-Founder + CEO Jason Bock revealed the companies’ findings at the 30th annual International Society for Cell & Gene Therapy (ISCT) Conference in Vancouver, Canada.
- Manufacturing remains a critical barrier to scaling cell and gene therapies, thus far, limiting the clinical and commercial impact of this life-saving new class of therapies.
- Through their collaboration , Ori and CTMC evaluated the IRO platform's capabilities to manufacture a clinical-stage CAR-T asset, showing superior biological performance when compared to the current manufacturing process.
- “This data showcases the ability of the IRO platform to provide superior biological performance, accelerate therapy development, and scale the clinical and commercial impact of these incredible therapies.